產(chǎn)品詳情
簡(jiǎn)單介紹：
Anti-phospho-PLB(Ser16)抗體產(chǎn)品質(zhì)量穩(wěn)定，實(shí)驗(yàn)效果明顯，貨期快，價(jià)格優(yōu)惠，歡迎垂詢訂購(gòu)！我公司長(zhǎng)期供應(yīng)**組化抗體、WB抗體、**組化試劑盒和抗體試驗(yàn)所需全部相關(guān)試劑、熒光標(biāo)記抗體、單克隆抗體、多克隆抗體、各種標(biāo)記的二抗IgG/IgM/IgD/IgA等科研實(shí)驗(yàn)抗體。Anti-phospho-PLB(Ser16)抗體用于**組化實(shí)驗(yàn),WB實(shí)驗(yàn),相應(yīng)的標(biāo)記抗體有HRP標(biāo)記抗體,FITC標(biāo)記,BIO等。
詳情介紹：
Rabbit Anti-phospho-PLB(Ser16)
Cat. Number:
Anti-phospho-PLB(Ser16)抗體KL-2984R
Quantity size:
0.1ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
Defects in PLN are the cause of cardiomyopathy dilated type 1P (CMD1P) . Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and Anti-phospho-PLB(Ser16)抗體arrhythmia. Patients are at risk of premature death. Defects in PLN are the cause of cardiomyopathy familial hypertrophic type 18 (CMH18) . CMH18 is a hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death.
Also known as:
Phospholamban (phospho S16); p-Phospholamban (phospho S16); p-PLB(S16); Cardiac phospholamban; CMD1P; PLB; Anti-phospho-PLB(Ser16)抗體PLN; PPLA_HUMAN.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Dog, Pig, Cow, Rabbit, .
●
Immunogen: KLH conjugated synthesised phosphopeptide derived from human Cardiac phospholamban around theAnti-phospho-PLB(Ser16)抗體phosphorylation site of Ser16.
●
Predicted Molecular Weight: 5.7kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 Flow-Cyt=1:50-500 ICC=1:100-500 IF=1:100-500 Anti-phospho-PLB(Ser16)抗體
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
